X

Trial Profile

A Phase 2 Study of IGM-2323 in Follicular Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imvotamab (Primary)
Indications Follicular lymphoma
Focus Registrational; Therapeutic Use
Sponsors IGM Biosciences

Most Recent Events

08 Aug 2022 According to an IGM Biosciences media release, the company expects to provide an initial efficacy and safety update from this study later this year or in the first quarter of 2023.
29 Mar 2022 According to an IGM Biosciences media release, data from this study could potentially be used as the basis for accelerated review and approval of IGM-2323.
29 Mar 2022 Status changed from planning to recruiting, according to a IGM Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com